According to a previous study by Liu et al., activated neuroendocrine markers including CHGA predicted good progression-free and overall survival for patients with well-differentiated pancreatic neuroendocrine neoplasms (59). This evidence concerns the gene CHGA and pancreatic neuroendocrine neoplasm.